Frank Gleeson, MBA

Chief Executive Officer, Board Member

Frank Gleeson is an experienced business executive, VC investor and biotech entrepreneur. He has an extensive background in start-up situations spanning over a dozen companies where he has established teams, negotiated multiple transactions and secured funding in excess of $200M. In 2008, Frank co-founded Verio Therapeutics Inc. with Dr. Rudnicki. Subsequently, Frank arranged and negotiated a successful exit to Fate Therapeutics Inc., who acquired Verio in 2010.

Dr. Michael Rudnicki, FRS, OC, FRSC

Chief Scientific Officer, Board Member

Dr. Michael Rudnicki, FRS, OC, FRSC, is the Director – Regenerative Medicine at the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He serves as CEO of the Stem Cell Network of Canada. A Past Foreign Scholar of the Howard Hughes Medical Institute, Dr. Rudnicki holds 10 patents and has authored over 200 publications. He is a co-founder of Verio Therapeutics Inc. & Fate Therapeutics Inc.

Warren Whitehead

Chief Financial Officer

Mr. Warren Whitehead is a Chartered Professional Accountant (CPA) and Certified Management Accountant (CMA) who has held multiple senior financial management positions in several biotechnology and pharmaceutical companies, and is currently a Board Member of Aptose Biosciences. Mr. Whitehead was the former Chairman and Board Member of Plantform Corporation and a former Board Member of Telesta Therapeutics (TSX), which was acquired by Prometic Life Sciences in 2016. He served as the Chief Financial Officer of ProMIS Neurosciences Inc. (formerly Amorfix Life Sciences Ltd.) from 2013 to 2015, a TSX-listed company targeting detection and effective treatment of Alzheimer’s disease and amyotrophic lateral sclerosis. Previously, from 2006 to 2008, he was the Chief Financial Officer of Arius Research Inc., a TSX-listed company developing anti-cancer antibodies, where he provided financial guidance and leadership during the acquisition of Arius by Roche in 2008. He was also the former Chief Financial Officer of Labopharm Inc. from 2000 to 2006, where he completed a series of public equity financings, including a cross-border Nasdaq offering. Other positions include Chief Financial Officer of Resolution Pharmaceuticals Inc., and a position in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead holds an MBA and BComm from the University of Windsor and a BA from the University of Western Ontario.

Dr. Sridhar Narayan, MBA

Vice President, Drug Discovery and Program Leadership

Dr. Sridhar Narayan is a veteran medicinal chemist with extensive success working with major pharmaceutical and biotech companies such as Eisai, AstraZeneca, Navitor, and Appili. Sridhar brings to Satellos a proven track record of advancing compounds into development in a number of disease areas.

Dr. Ryan Mitchell

Director, Business Development

Prior to joining Satellos, Dr. Mitchell worked with Bloom Burton Securities Inc. as a scientific consultant where he contributed to monetization planning efforts for clients ranging from pre-seed start-ups to large multinational pharmaceutical companies. Ryan completed his graduate work at the McMaster University Stem Cell and Cancer Research Institute where he authored numerous publications in high impact journals such as Nature and Cell.

Board of Directors

Chair, Geoff MacKay

President & CEO AVROBIO, Inc.

Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.

Brian Bloom

Board Member

Board Member – Brian Bloom (Co-founder, Chairman & CEO Bloom Burton & Co) – Brian serves on the Board of Directors of Triumvira Immunologics, Appili Therapeutics, and Qing Bile Therapeutics. Brian is also on the Faculty of Science Dean’s Advisory Board at McMaster University. Brian was formerly the Chairman of the Board of Grey Wolf Animal Health, a member of the Life Sciences Advisory Board at the National Research Council of Canada and on the Boards of BIOTECanada and the Baycrest Foundation. Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics. Brian is the proud recipient of the McMaster University 2017 Distinguished Alumni Award in Science.

John Holyoake

Board Member

John Holyoake, DPhil (Managing Director, Investment Banking, Bloom Burton & Co) – at Bloom Burton, John’s responsibilities include M&A advisory, licensing advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. John is a member of the Board of Directors of the Canadian Glycomics Network and was a founding Board member of Triumvira Immunologics. Additionally, John is a member of the Core Evaluation Team for Genome Canada’s Genomic Applications Partnership Program. John joined Bloom Burton from a background of industry experience in the clinical stage oncology company TenX BioPharma and at the life science consulting group SHI Link. John holds a Master’s in Biochemistry from the University of Oxford, and received his doctorate from the same institution.

Dr. William McVicar

Board Member

Dr. McVicar’s career in the pharmaceutical industry spans more than 30 years. He has held numerous high ranking positions, leading teams at Sandoz, Novartis, RPR Gencell, Sepracor, Innotek Pharmaceuticals, Flex Pharmaceuticals, and Salarius pharmaceuticals. During his career, Dr. McVicar has personally overseen the development of multiple drug candidates from early testing all the way through to approval, including BROVANA®, XOPENEX MDI®, and XOPENEX’s pediatric approval. As a C-suite executive Dr. McVicar has raised well over $100MM in venture financing, lead numerous licensing transactions, and has successful executed the merger of Flex and Salarius Pharmaceuticals, where he remains Chair of the board of Directors. Dr. McVicar earned his B.S. in Chemistry from SUNY College at Oneonta and his Ph.D. in Chemistry from the University of Vermont. He is an author on numerous peer-reviewed scientific publications and an inventor on 15 issued US patents.

Bill Jarosz

Board Member

William Jarosz was the Chief Executive Officer of iCo Therapeutics, Inc. from 2020 until 2021 and currently the President of Satellos’ subsidiary Amphotericin B Technologies, Inc. He is currently a Founding Partner at Cartesian Capital Group, LLC, a global investment management firm. From 1997 until 2005, Mr. Jarosz served as Managing Director and General Counsel of AIG Capital Partners, a subsidiary of American International Group, Inc., and as Managing Director of the AIG- Brunswick Millennium Fund. While at AIG Capital Partners, Mr. Jarosz oversaw global private equity transactions for the firm’s various private equity funds. Prior to joining AIG in 1997, Mr. Jarosz practiced law at Debevoise & Plimpton, specializing in international private equity investment and Russian corporate and securities laws. Mr. Jarosz also served as a consultant to the World Bank on the regulation of Foreign Direct Investment in emerging markets. Mr. Jarosz is a graduate of the University of Montana and received an MA in Law and Diplomacy from the Fletcher School at Tufts University, and a JD from Harvard Law School.